These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 11040851)

  • 1. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
    Buttar NS; Wang KK
    Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2 inhibitors: new drugs for the management of pain and inflammation.
    Hutchins V; Hutchins B
    Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
    [No Abstract]   [Full Text] [Related]  

  • 3. COX-1 and COX-2 in health and disease.
    Adelizzi RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S7-12. PubMed ID: 10643175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2: a therapeutic target.
    Turini ME; DuBois RN
    Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease.
    Willoughby DA; Moore AR; Colville-Nash PR
    Lancet; 2000 Feb; 355(9204):646-8. PubMed ID: 10696997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COX-1 and COX-2 inhibition: current status and future perspective.
    Greyn J; Lauwers MH; Vanlersberghe C; Camu F
    Acta Anaesthesiol Belg; 1998; 49(3):175-83. PubMed ID: 9844704
    [No Abstract]   [Full Text] [Related]  

  • 8. COX-2-specific inhibition: implications for clinical practice.
    Pascucci RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S18-22. PubMed ID: 10643177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
    Pascucci RA
    J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2 inhibitors: promise or peril?
    Mengle-Gaw LJ; Schwartz BD
    Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
    van der Bijl P; van der Bijl P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of cyclooxygenase-1 and -2 in health and disease.
    Lipsky PE
    Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):8-12. PubMed ID: 10193997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin and NSAID sensitivity.
    Stevenson DD
    Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multisystem adverse effects of NSAID therapy.
    James DS
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S1-7. PubMed ID: 10643174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.